Recent Advances in Melanoma Staging and Therapy by Sondak, Vernon K. et al.
Recent Advances in Melanoma Staging and Therapy
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Background: Recent advances in the staging and treatment of melanoma were reviewed.
Methods: A literature-based review was performed.
Results: The current American Joint Committee on Cancer (AJCC) Staging system for melanoma
has several drawbacks. Proposed changes in the staging system to take into account simplified tumor
thickness categories, tumor ulceration, and the number (rather than size) of nodal metastases will
allow stage groups with more uniform prognosis. The widespread application of sentinel lymph
node biopsy for nodal staging allows accurate nodal staging with minimal morbidity. Reverse
transcriptase-polymerase chain reaction (RT-PCR) is a very sensitive molecular staging test that
may prove useful for identifying early metastatic disease. There is finally an effective adjuvant
therapy for melanoma—interferon alfa-2b. Other adjuvant therapies, including melanoma vaccines,
may provide effective and less toxic alternatives. New immunotherapy and gene therapy strategies
are under investigation.
Conclusions: Ongoing and future adjuvant therapy trials will benefit from improved melanoma
staging by accrual of homogeneous groups of patients. New approaches for adjuvant therapy await
completion of clinical trials. Innovative new therapies offer hope for patients with advanced disease.
Key Words: Melanoma—Sentinel lymph node—Adjuvant therapy—Immunotherapy—Gene
therapy.
The rapid increase in the incidence of melanoma has
been paralleled by expanded research efforts to improve
the outcome for patients with this disease. As a result,
advances have been made in our ability to accurately
determine the stage of disease, effective adjuvant therapy
has been developed, and promising innovative treatment
strategies are under investigation.
ADVANCES IN THE STAGING OF MELANOMA
Advances in the treatment of cancer often result from
prospective, randomized clinical trials. To test new ther-
apies, it is imperative to identify the proper population of
patients to study. Staging systems allow us to group
patients of similar prognosis to test new therapies, or to
determine who is most likely to benefit from existing
treatments. There are problems inherent in studying ei-
ther a population with a very good prognosis, in whom it
is difficult to demonstrate small differences in outcome,
or a population with a very poor prognosis, in whom
additional therapy is unlikely to provide any benefit.
Furthermore, studies that include extremely heteroge-
neous populations of patients with both good and poor
prognoses can be difficult to interpret. One key to suc-
cessful clinical studies is proper identification of the
groups of patients that are most likely to benefit from the
therapy under investigation.
Proposed Changes to the AJCC Staging System
The current American Joint Committee on Cancer
(AJCC) staging system for melanoma, established in
1992, has several drawbacks (Table 1). Improvements to
the staging system have been suggested by Buzaid and
colleagues, based on an updated analysis of the Univer-
sity of Alabama at Birmingham (UAB) and Sydney
Melanoma Unit (SMU) databases.1
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The Breslow thickness categories used in the present
staging system ( 0.75, 0.76–1.50, 1.51–4.0, and  4.0
mm) are cumbersome and not as predictive of survival as
the simplified categories based on whole integers (1.0,
1.01–2.0, 2.01–4.0, and  4.0 mm). Tumor ulceration,
long known to be an important prognostic factor, is not
taken into account in the current AJCC staging system.
Finally, it is clear that the most important factor for nodal
staging is the number—not the size—of nodal metasta-
ses.
Proposed changes improve the staging system by de-
fining stage groupings according to more similar prog-
nosis (Table 2). One thing the proposed changes do not
TABLE 1. The 1992 American Joint Committee on Cancer
staging system for cutaneous melanoma
Definitions
Primary tumor (pT)*
pTX Primary tumor cannot be assessed
pT0 No evidence of primary tumor
pTis Melanoma in situ (atypical melanotic hyperplasia,
severe melanotic dysplasia), not an invasive lesion
(Clark’s level I)
pT1 Tumor 0.75 mm in thickness and invades the
papillary dermis (Clark’s level II)
pT2 Tumor more than 0.75 mm but not more than 1.5
mm in thickness and/or invades the papillary
reticular-dermal interface (Clark’s level III)
pT3 Tumor more than 1.5 mm but not more than 4 mm
in thickness and/or invades the reticular dermis
(Clark’s level IV)
pT3a Tumor more than 1.5 mm but not more than 3 mm
in thickness
pT3b Tumor more than 3 mm but not more than 4 mm in
thickness
pT4 Tumor more than 4 mm in thickness and/or invades
the subcutaneous tissue (Clark’s level V) and/or
satellite(s) within 2 cm of the primary tumor
pT4a Tumor more than 4 mm in thickness and/or invades
the subcutaneous tissue
pT4b Satellite(s) within 2 cm of primary tumor
Lymph node
(N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis 3 cm in greatest dimension in any
regional lymph node(s)
N2 Metastasis more than 3 cm in greatest dimension in
any regional lymph node(s) and/or in-transit
metastasis
N2a Metastasis more than 3 cm in greatest dimension in
any regional lymph node(s)
N2b In-transit metastasis
N2c Both (N2a and N2b)
Distant metastasis (M)
MX Presence of distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Metastasis in skin or subcutaneous tissue or lymph
node(s) beyond the regional lymph nodes
M1b Visceral metastasis
Stage grouping
I pT1 N0 M0
pT2 N0 M0
II pT3 N0 M0
pT4 N0 M0
III Any pT N1 M0
Any pT N2 M0
IV Any pT Any N M1
* In case of discrepancy between tumor thickness and level, the pT
category is based on the less favorable finding.
TABLE 2. Suggested definitions for a new staging system
Definitions
Primary tumor (T)
TX Primary tumor cannot be assessed
TO No evidence of primary tumor (unknown primary)
Tis Melanoma in situ (atypical melanotic hyperplasia,
severe melanotic dysplasia), not an invasive lesion
T1 Tumor 1 mm in thickness
T1a no ulceration
T1b with ulceration








T4 Tumor more than 4 mm in thickness
T4a no ulceration
T4b with ulceration
Regional lymph node (N)
cN Regional node(s) are clinically shown to be involved
pN Regional node(s) are pathologically shown to be
involved, but the number of positive nodes is not
available
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis (clarify “c” or “p”)
N1 Metastasis to only one regional node
N2 Metastasis to two but no more than four regional
nodes
N3 Metastases to more than four regional nodes or
presence of extranodal extension, regardless of the
number of positive nodes, or bilateral regional
nodal metastases for primary lesions with
ambiguous drainage
Regional skin/subcutaneous (S)
SX Presence of regional skin metastases cannot be
assessed
S0 No regional skin/subcutaneous metastasis
cS Regional skin/subcutaneous metastases detected by
physical examination
pS Regional skin/subcutaneous metastases (including
microsatellites) pathologically confirmed
Distant metastasis (M)
MX Presence of distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Metastasis in skin or subcutaneous tissue or lymph
node(s) beyond the regional lymph nodes
M1b Visceral metastasis
Note: Patients with local recurrence, in-transit, or satellite lesions in
the head and neck region or trunk have a worse prognosis than patients
with lesions of an extremity.
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accomplish very well, however, is simplicity. It is hoped
that the AJCC will adopt many of these proposed
changes, perhaps in a simplified version that accurately
reflects patient outcome.
Elective Lymph Node Dissection
For many years, proponents of elective lymph node
dissection (ELND) have argued that early removal of
regional lymph nodes imparts a survival advantage.
However, four prospective, randomized trials have failed
to show an overall survival benefit for ELND.2–5
A recent update of the Intergroup Melanoma Surgical
Trial of ELND vs. observation of clinically negative
regional lymph node basins for patients with intermedi-
ate-thickness melanoma again demonstrated no overall
survival benefit for ELND. However, subgroup analysis
identified some patients who did appear to benefit from
ELND.
The following two questions get to the heart of the
issue: (1) Does ELND provide a survival advantage for
patients with clinically node-negative melanoma? and
(2) Does lymph node dissection ever cure patients with
nodal metastases?
Four randomized prospective trials have failed to dem-
onstrate a statistically significant improvement in overall
survival for patients undergoing ELND when all ran-
domized patients are analyzed. However, a survival ben-
efit has been demonstrated in some subgroups of pa-
tients.
Before effective adjuvant therapy for melanoma was
available, some patients were cured by therapeutic resec-
tion of nodal metastases—even palpable nodal metasta-
ses. In fact, the 10-year survival rate for patients with a
single positive lymph node (palpable or nonpalpable) is
40% to 60%, substantially better than that for patients
with multiple positive nodes.1
Why It Has Been Difficult to Demonstrate an
Overall Survival Advantage in Randomized Trials
of ELND
This is a classic case of the drawbacks of studying a
heterogeneous patient population. Most patients with in-
termediate-thickness melanomas do not develop nodal
metastases. In fact, only about 20% of patients in the
observation arm of the Intergroup Melanoma Surgical
Trial developed nodal metastases. Therefore, only 20%
of the patients who underwent ELND could potentially
benefit from early removal of nodal micrometastases. If
early removal of nodal micrometastases imparts a sur-
vival advantage similar to other forms of adjuvant ther-
apy (i.e., 25% to 50%), then only 25% to 50% of the 20%
of patients with nodal metastases, or 5% to 10% of
patients overall, would enjoy a survival benefit. That is,
in fact, the magnitude of the benefit actually demon-
strated. When we examined the results of the Intergroup
Trial, there was a 5% advantage overall for ELND.6
Although this is not statistically significant, the sample
size of this trial does not allow sufficient statistical
power to detect a 5% difference in survival. Because of
the heterogeneous population, inclusion of the node-
negative patients causes a substantial dilution of survival
benefit. Analysis of prospectively stratified subgroups,
however, reveals more substantial differences in 10-year
survival among selected groups that are in line with the
above calculation. For example, there was a 29% reduc-
tion in mortality in patients with nonulcerated melano-
mas, a 27% reduction in mortality in patients with ex-
tremity melanomas, and a 35% reduction in mortality for
patients with melanomas of Breslow thickness 1 to 2
mm. All of these were statistically significant. Although
age was not a prospective stratification criterion, it ap-
pears that patients younger than 61 years of age benefit
from ELND.
A convincing case therefore can be made for early
removal of occult nodal metastases. This is supported by
the results of the WHO Melanoma Program 14, in which
the 5-year survival rate in patients with occult regional
node metastases detected at ELND was 48.2%, versus
26.6% for patients in whom regional node dissection was
delayed until the time of appearance of clinically evident
nodal metastases.5 Because the prognosis after therapeu-
tic lymph node dissection alone is so much better for
patients with a single positive lymph node compared to
those with multiple positive nodes,1 it makes sense that
early therapeutic lymphadenectomy should save lives. It
probably is better to perform lymphadenectomy for a
single microscopically positive node than to wait until
the nodal disease is palpable, by which time more than
one node often is positive.
Most patients who currently undergo ELND suffer the
morbidity of lymph node dissection without any possible
therapeutic benefit. The optimal situation would be to
identify those patients who actually have nodal micro-
metastases, and reserve regional lymphadenectomy for
these patients. It is now possible to identify those patients
using sentinel lymph node biopsy.
The Role of Sentinel Lymph Node Biopsy
Morton and colleagues first demonstrated the feasibil-
ity and accuracy of sentinel lymph node biopsy for nodal
staging of patients with melanoma,7 and other studies
have documented the accuracy of the technique.8–20 The
procedure is performed on a outpatient basis, and can be
done under local anesthesia. Sentinel lymph node biopsy
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has the distinct advantage of providing accurate nodal
staging information with a minimally invasive operation,
which essentially involves the morbidity of a lymph node
biopsy. Those patients who are found to have nodal
metastases can then be selected for more aggressive
treatment, including lymph node dissection and adjuvant
therapy. Patients without nodal metastases suffer little
morbidity from the procedure, and have a substantially
better prognosis than do those with nodal metastases.
In addition to the obvious advantage in terms of mor-
bidity, sentinel lymph node biopsy probably is more
accurate than ELND for determining nodal stage. ELND
specimens undergo routine histology (1 or 2 histological
sections from the center of each node), whereas exami-
nation of the sentinel node involves serial sections and
immunohistochemical evaluation, which often detects
tiny micrometastases not seen on routine histology. Data
from the Intergroup Surgical Trial indicate that routine
histology of ELND specimens underestimates the num-
ber of patients with nodal metastases (Table 3). Even
with serial sectioning and immunohistochemistry of sen-
tinel nodes, the number of patients who ultimately will
develop nodal metastases probably is underestimated
(Fig. 1).21
Molecular Staging of Melanoma
The reason for the discrepancy between estimated and
actual numbers of patients who develop metastases may
be that some patients have “submicroscopic” lymph node
metastases that are not detected even with careful patho-
logic analysis. Reverse transcriptase polymerase chain
reaction (RT-PCR) analysis of lymph nodes is a very
sensitive test that can detect one melanoma cell in 1
million normal cells. RT-PCR detects specific mRNA
expressed by melanoma cells.22 It has been reported that
RT-PCR detection of tyrosinase mRNA in histologically
negative sentinel nodes correlates with decreased dis-
ease-free and overall survival.23 Routine RT-PCR anal-
ysis of sentinel lymph nodes may improve our ability to
predict those patients who are at higher risk for recur-
rence.
It also has been demonstrated that RT-PCR analysis of
tyrosinase mRNA in peripheral blood correlates with
prognosis for patients with melanoma.24 Although there
are conflicting reports, RT-PCR analysis of peripheral
blood samples may prove to be an important molecular
staging test to determine the need for and effectiveness
of adjuvant therapy, and for follow-up.
ADJUVANT THERAPY OF MELANOMA
Historical Perspective
The search for effective adjuvant therapy for patients
with resected high-risk melanoma has resulted in many
clinical trials conducted over the past three decades.
Initial studies employed a series of nonspecific immuno-
stimulants. Bacille Calmette-Guérin (BCG) induces re-
gression in up to 80% of cutaneous melanoma metastases
when injected intralesionally.25,26 Up to 20% of unin-
jected lesions in the same patient also may regress.
Interest in the adjuvant use of BCG arose following the
suggestion of benefit in nonrandomized trials, but no
benefit was demonstrated in nine subsequent prospective
randomized trials.26
TABLE 3. Incidence of regional node metastases
(Intergroup Melanoma Surgical Trial)
Group
Tumor thickness
1–2 mm 2–3 mm 3–4 mm






FIG. 1. Estimated risk of developing clinically evident (palpable)
regional nodal metastases within 3 years or distant metastases within 5
years according to tumor thickness. (From Balch CM, Cascinelli N,
Sim FH, et al. Elective lymph node dissection: results of prospective
randomized trials. In: Balch CM, Houghton AN, Sober AJ, Soong S-J,
eds. Cutaneous Melanoma. St. Louis: Quality Medical Publishing,
1998:405–18, with permission.)
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Adjuvant use of Cryptosporidium parvum, another
nonspecific microbial immunostimulant, also looked
promising based on retrospective studies. Again, pro-
spective, randomized trials failed to substantiate the ef-
ficacy of this agent. Levamisole, yet another nonspecific
immunostimulant, showed no benefit in three of four
randomized trials. Other agents tested in randomized
trials in the adjuvant setting but not found to be of benefit
include dacarbazine (DTIC) chemotherapy alone or in
combination with other cytotoxic drugs, DTIC plus im-
munostimulants, transfer factor, thymosin, isoprinosine,
megestrol acetate, and retinoids.26
These studies demonstrate the critical importance of
prospective randomized trials to ultimately prove or dis-
prove the clinical efficacy of adjuvant therapies. Retro-
spective analyses repeatedly were found to be mislead-
ing. It also became clear that the next generation of
clinical trials would require more powerful agents and
large enough sample sizes to detect clinically relevant
differences in disease-free and overall survival.
Melanoma Vaccines
Development and testing of melanoma vaccines for
both adjuvant use and treatment of advanced disease
have been ongoing for many years, but until recently,
there have been few efforts to subject vaccines to the
rigors of phase III randomized trials. Vaccines currently
are being tested in the adjuvant therapy of resected stage
II and III melanoma. A large Southwest Oncology Group
(SWOG) trial involving over 670 patients has compared
2 years of treatment with an allogeneic melanoma cell
lysate to observation in patients with stage IIA mela-
noma (primary tumor 1.5–4.0 mm and clinically nega-
tive nodes). Results are expected sometime in 1999. A
new Intergroup trial comparing a ganglioside vaccine
(GM2-KLH) to high-dose interferon alfa-2b currently is
underway, and a large multicenter randomized trial of an
allogeneic whole-cell melanoma vaccine (coordinated by
the John Wayne Cancer Institute in Santa Monica, CA)
recently began. In addition to allogeneic vaccines, autol-
ogous defined antigen vaccines—involving both peptide
and ganglioside antigens—are entering clinical trials in
the adjuvant therapy of melanoma.
Interferons
In the 1980s, attention turned to two very potent,
well-defined immunostimulants, interferon-gamma and
interferon-alpha. In 1986, the Southwest Oncology
Group studied adjuvant interferon-gamma in high-risk
patients in a randomized prospective trial. Patients re-
ceiving interferon-gamma on the SWOG trial had no
clinical benefit—and may actually have done worse—
compared to patients receiving no adjuvant therapy.27 At
about the same time, adjuvant interferon-alpha was stud-
ied in two trials conducted by the North Central Cancer
Treatment Group (NCCTG) and the Eastern Cooperative
Oncology Group (ECOG). The NCCTG trial employed a
high dose of interferon alfa-2a three times per week for
3 months. Overall, the NCCTG results showed no sig-
nificant benefit for disease-free or overall survival. For
the subgroup of node-positive patients, however, a sta-
tistically significant improvement in disease-free sur-
vival was demonstrated, with 40% alive and disease-free
at 5 years in the treatment group compared to 30% in the
control group.28
Interferon Alfa-2b
The ECOG trial, E1684, was the first study to dem-
onstrate a survival benefit for any form of adjuvant
therapy for melanoma. This study used high-dose intra-
venous interferon alfa-2b (20 million international
units/m2 5 days per week) for 1 month, followed by
subcutaneous injections (10 million IU/m2 3 times per
week) for 48 weeks. Patients entered into this study had
thick (4 mm) primary lesions with pathologically neg-
ative nodes (AJCC Stage IIB) or any thickness primary
with pathologically positive nodes (Stage III). Prognostic
factors were well balanced between the treatment and
control group, with two important exceptions: (1) the
number of positive nodes in the Stage III patients was not
recorded, so it is unknown if the groups were balanced
with regard to this critical prognostic factor; and (2) the
Stage IIB patients (those with node-negative thick pri-
mary lesions) randomized to interferon had more ulcer-
ated lesions, a poor prognostic factor, than did those in
the observation group.29
For all eligible patients in this trial, interferon therapy
resulted in an improvement in 5-year disease-free sur-
vival from 36% to 37%. The 5-year survival rate im-
proved from 37% to 46% with interferon therapy. These
results were statistically significant (P  .02) and rep-
resent the first evidence of overall survival benefit for
any adjuvant therapy in patients with high-risk mela-
noma. The benefit was greatest for node-positive pa-
tients: the 5-year risk of relapse improved 66%, and the
5-year risk of mortality improved 40%.29
The ECOG trial deliberately chose to assess an inter-
feron dose at or near the maximum tolerable dose. Tox-
icity with this regimen was significant, and 2 of the 143
patients in the treatment group died as a result of therapy.
Adverse constitutional and neuropsychiatric symptoms
(e.g., headache, depression) and laboratory findings of
myelosuppression and hepatotoxicity occurred often.
Still, with appropriate monitoring and dose modification
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when necessary, 74% of the patients were able to com-
plete a full course of therapy.
An interim analysis of ECOG Trial 1690, a follow-up
study that included patients similar to those included in
ECOG Trial 1684, recently has been reported.30 This
three-arm trial randomized patients to observation, low-
dose interferon alfa-2b, or high-dose interferon alfa-2b.
With 52 months median follow-up, high-dose interferon
alfa-2b was found to significantly improve relapse-free,
but not overall, survival. The overall survival of the
observation group, however, was substantially better
than that seen in ECOG Trial 1684. It seems that adju-
vant interferon alfa-2b therapy of high-risk melanoma
patients imparts a reproducible relapse-free survival ad-
vantage. The magnitude of benefit in terms of overall
survival has been brought into question. Further analysis
and follow-up of patients in ECOG Trial 1690 are nec-
essary. For example, many of the patients who recurred
in the observation group may have been treated subse-
quently with interferon alfa-2b, which could confound
the results.
Low-dose interferon alfa-2b had no effect on either
disease-free or overall survival in ECOG 1690. A World
Health Organization study of low-dose interferon alfa-2a
(3 million IU 3 times per week over 3 years) in patients
with resected, node-positive melanoma recently was re-
ported as a negative trial as well.31 These results indicate
that low-dose interferons are not effective as is adjuvant
therapy for melanoma.
Interferons in Stage II Melanoma
Preliminary results of three European studies have
suggested a disease-free survival advantage (but, as yet,
no overall survival advantage) from 12 to 36 months of
low-dose (3 million IU three times a week) interferon-
alpha in patients with clinical stage II melanoma.31–34
Follow-up of these studies is required to determine if
these results hold up over time and translate into an
overall survival advantage. These studies have been crit-
icized because surgical staging of regional lymph nodes
was not performed.35 Many patients with clinically neg-
ative nodes (20% to 25%) actually have microscopic
nodal metastases that are not palpable. Many of the
recurrences are in the regional lymph nodes; however,
the most effective therapy for prevention of nodal recur-
rence is lymph node dissection, not interferon, for posi-
tive nodes.
Because of the substantial difference in prognosis for
patients with intermediate-thickness melanomas with
metastases versus those without nodal metastases, adju-
vant therapy trials involving such heterogeneous groups
of patients are difficult to interpret. With the availability
of sentinel lymph node biopsy for accurate nodal staging,
the indiscriminate use of adjuvant therapy based on clin-
ical staging of regional lymph nodes is not likely to gain
wide acceptance.
THE SUNBELT MELANOMA TRIAL:
COMBINING ACCURATE STAGING AND
ADJUVANT THERAPY
The Sunbelt Melanoma Trial is a multi-institutional,
prospective, randomized trial that integrates the advances
in melanoma staging and adjuvant therapy. The principal
goal is to use ultra-staging to identify those patients who
are most likely to benefit from adjuvant therapy. The
central hypothesis is that adjuvant interferon alfa-2b
therapy plus regional lymph node dissection is more
effective than lymph node dissection alone at prolonging
disease-free and overall survival for patients with early
nodal metastasis. Early nodal metastasis is defined as a
single microscopically positive sentinel node only, or
RT-PCR-positive—only positive sentinel nodes.
All patients who are younger than 71 years old with
melanoma 1.0 mm Breslow thickness, have no palpa-
ble lymph nodes, have no evidence of distant metastasis,
and who are otherwise fit to receive interferon alfa-2b
therapy are eligible (Fig. 2). At the time of lymphatic
mapping and sentinel lymph node biopsy, a portion of
each sentinel node is frozen and stored at 70°C for
possible RT-PCR analysis at a later time. The remaining
lymph node is examined by routine histology, serial
sectioning, and immunohistochemical staining for S-100
protein. With a median Breslow thickness of 2.3 mm,
25% of patients have had a positive sentinel node by
histology or immunohistochemistry. This attests to the
sensitivity of the pathological analysis of the sentinel
nodes.
Patients with histologically or immunohistochemically
positive sentinel nodes are eligible for Protocol A. All
patients undergo regional lymph node dissection. Pa-
tients with one histologically or immunohistochemically
positive sentinel node as the only nodal metastasis are
randomized to either observation or high-dose adjuvant
interferon alfa-2b therapy, with stratification by Breslow
thickness (1.0–2.0 mm, 2.0 to 4.0 mm, or 4.0 mm).
Patients with more than one histologically or immu-
nohistochemically positive sentinel node, any evidence
of extracapsular extension of the tumor, or any non-
sentinel node that contains metastatic melanoma, are not
randomized but are treated with standard high-dose in-
terferon alfa-2b. These patients are followed to deter-
mine the predictive value of prospective peripheral blood
PCR analysis for survival and recurrence. In this way,
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valuable molecular staging information will be obtained
from this group of patients who receive standard adju-
vant therapy. This group of patients also will be eligible
to go off study and participate in other protocols, if
desired, so as not to limit the therapeutic options of
patients with multiple positive lymph nodes.
Patients with histologically and immunohistochemi-
cally negative sentinel nodes are eligible for Protocol B.
After informed consent is obtained, the stored portion of
the sentinel node is evaluated by RT-PCR analysis.
Markers analyzed include tyrosinase, MART1, Mage3,
and gp100. A positive PCR test is defined as detection of
tyrosinase plus at least one other marker. If the sentinel
node is negative by RT-PCR analysis, the patients are
observed. If the sentinel node is positive by RT-PCR
analysis, the patients are stratified by tumor thickness
and randomized to one of three arms: observation, lymph
node dissection, or lymph node dissection plus interferon
alfa-2b. Protocol B not only will define in a prospective
fashion the natural history of patients with PCR-only–
positive sentinel nodes, but also will determine if adju-
vant interferon alfa-2b therapy plus lymphadenectomy is
superior to lymphadenectomy alone in terms of disease-
free and overall survival. All patients also will undergo
prospective analysis of peripheral blood by RT-PCR to
determine the value of this molecular staging test.
The Sunbelt Melanoma Trial involves over 50 centers
nationwide; over 700 patients have been enrolled in the
study in just over 18 months. This study offers a unique
opportunity to use the advances in melanoma staging to
determine the need for adjuvant therapy. The importance
of the Sunbelt Melanoma Trial is amplified by the in-
terim results of ECOG Trial 1690, because it is essential
to define precisely the subgroups of patients who benefit
from adjuvant therapy. This ongoing study promises to
yield important information that will be helpful in the
treatment of melanoma patients in years to come.
PROSPECTS FOR THE FUTURE
New therapies for patients with advanced melanoma
offer hope where once there was none. Patients with
unresectable systemic metastases have several options
for treatment, including chemotherapy, immunotherapy,
or gene therapy. Conventional chemotherapy offers some
hope of tumor response, but little chance for long-term
survival.36 New agents with activity against melanoma
are being developed. One such drug, temozolomide, is an
oral agent that has been shown to have acceptable tox-
icity and promising response rates in patients with met-
astatic melanoma.37
Durable complete responses have been achieved with
high-dose interleukin-2 (IL-2) alone.38,39 Biochemo-
therapy regimens include an aggressive combination of
IL-2, interferon alpha, and chemotherapy, and have dem-
onstrated response rates of up to 60%, with complete
response rates often in excess of 10%. Some of these
complete responses with IL-2–based therapy have been
observed for years. The demonstration of long-term com-
plete responses to immunotherapy or biochemotherapy
offers promise that refinements of such therapies may
lead to actual cure of patients with systemic metastases.
Further research is necessary to limit the toxicity of the
regimens and increase the complete response rate.
Various approaches to stimulating specific immune
responses against metastatic melanoma are under inves-
FIG. 2. Schematic describing Protocols
A and B in the Sunbelt Melanoma Trial.
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tigation. Dendritic cell therapy is a particularly interest-
ing approach. Dendritic cells are the most effective an-
tigen-presenting cells for primary immune responses,
and can be programmed to stimulate a vigorous immune
response against melanoma cells. Gene therapy using
dendritic cells is under investigation.40
Other gene therapy approaches also are being studied.
Gene therapy strategies have been designed to stimulate
anti-tumor immune responses, to express prodrug/suicide
genes, and to induce programmed cell death (apoptosis)
of melanoma cells.
CONCLUSIONS
Advances in the staging of melanoma promise to focus
adjuvant therapy on patients who are most likely to
benefit from it, and make interpretation of the results of
clinical trials easier. Sentinel lymph node biopsy has
made it possible to obtain accurate nodal staging infor-
mation with a minimally invasive operation. RT-PCR
analysis may be an important molecular staging test to
detect those patients at risk for recurrence. Interferon
alfa-2b has been established as the first Food and Drug
Administration–approved adjuvant therapy for mela-
noma. Melanoma vaccines offer the hope of less toxic
adjuvant therapy in the future. New immunotherapy and
gene therapy approaches to the treatment of advanced
disease offer the hope of long-term survival. These ad-
vances may usher in a new era of melanoma therapy in
which surgery is no longer the only effective weapon
against this malignancy.
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